The explicit going-concern warning and accelerating cash burn are the dominant signals. Traders should monitor for a dilutive capital raise or restructuring announcement, as the company's cash runway appears limited without additional financing. The commercial progress cited in the release does not offset the near-term solvency risk.
Price Chart
Executive Summary
Dyadic International reported Q2 2026 revenue of $961,138, essentially flat year-over-year (-0.6%), and a net loss of $2,123,884 ($-0.06 per share), widening from a $1,793,774 loss in Q2 2025. The company disclosed a material going-concern risk, stating there is substantial doubt about its ability to continue for 12 months following June 30, 2026, as cash and securities dropped to $4.8M from $8.6M at year-end 2025. While the press release highlights commercial progress and product shipments, the deteriorating cash position, widening operating loss, and explicit going-concern warning dominate the risk profile for this micro-cap biotech.
Key Financial Metrics
Key Facts
- Q2 2026 revenue was $961,138, down 0.6% YoY from $966,630.
- Net loss widened to $2,123,884 ($-0.06/share) from $1,793,774 ($-0.06/share) in Q2 2025.
- Cash, cash equivalents, restricted cash, and investment-grade securities fell to $4,794,798 as of June 30, 2026, from $8,587,289 at December 31, 2025.
- Management disclosed substantial doubt about the company's ability to continue as a going concern for the 12 months following June 30, 2026.
- Loss from operations increased 18.8% to $2,054,204 from $1,729,068 in the prior-year quarter.
- Stockholders' equity turned negative to ($2,387,244) from positive $1,232,410 at year-end 2025.
Financial Impact
Cash burn of ~$3.8M in H1 2026; going-concern risk flagged; net loss of $2.1M in Q2 alone.
Risk Factors
- Going-concern risk: substantial doubt about ability to continue operations for 12 months.
- Cash burn: cash and securities declined by ~44% in H1 2026, from $8.6M to $4.8M.
- Dilution risk: management flagged the dilutive impact of a capital raise to mitigate going-concern risk.
- Negative equity: stockholders' deficit of ($2.4M) as of June 30, 2026.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-037257 |
| Document: form8-k.htm | 0001493152-26-037257 |
| Document: 0001493152-26-037257-index-headers.html | 0001493152-26-037257 |
| Document: 0001493152-26-037257-index.html | 0001493152-26-037257 |
| Document: 0001493152-26-037257.txt | 0001493152-26-037257 |
| 8-K Data (Synthetic) | 0001493152-26-037257 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | SC 13G | $0.4194 | awaiting T+20 | — | $0.3900 (−7.01%) |
Sep 25, 2026 4w ago | 8-K | $0.4650 $0.4160 | ▲ +10.54% | ▲ +10.51% | $0.3900 (+16.13%) |
Sep 21, 2026 5w ago | EFFECT | $0.4010 $0.3809 | ▲ +5.01% | ▲ +4.10% | $0.3900 (+2.74%) |
Aug 14, 2026 10w ago | 8-K | $0.7751 $0.4244 | ▲ +45.25% | ▲ +43.25% | $0.3900 (+49.68%) |
Aug 12, 2026 10w ago | 8-K | $0.8800 $0.4898 | ▲ +44.34% | ▲ +42.44% | $0.3900 (+55.68%) |
Aug 12, 2026 10w ago | Press Release | $0.8800 $0.4898 | ▲ +44.34% | ▲ +42.44% | $0.3900 (+55.68%) |
Jul 24, 2026 13w ago | 8-K | $1.19 $0.6900 | ▼ −42.02% | ▼ −45.64% | $0.3900 (−67.23%) |
Jun 18, 2026 18w ago | DEFA14A | $0.7820 $1.19 | ▼ −52.17% | ▼ −51.64% | $0.3900 (+50.13%) |
May 28, 2026 21w ago | 8-K | $0.7100 $0.8010 | ▲ +12.82% | ▲ +15.96% | $0.3900 (−45.07%) |
Mar 25, 2026 30w ago | Press Release | $0.7000 $0.8600 | ▲ +22.86% | ▲ +12.19% | $0.3900 (−44.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers